About Tymora Analytical

  Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow detection of active exosome protein and phosphoprotein cancer markers directly from plasma, urine or saliva. As a platform to discover, validate and routinely detect diagnostic markers, our unique approach offers enormous potential to find signaling proteins in biofluids that were not previously accessible.   


Tymora’s technologies have been recognized internationally as novel, highly-effective and cost-efficient approaches to carry out proteomic and phosphorylation analyses. Tymora has received multiple NSF and NIH SBIR/STTR grants to further develop new applications of the technologies.

Tymora is open to collaborations with partners interested in our technology for design and validation of early disease detection tests, cancer monitoring post-treatment, or for companion diagnostic assays for pipeline therapies.

Tymora FCOI Policy

Here’s a better way to analyze EV (exosome) proteins and PTMs.

We’ve developed an improved approach to analyze 

EV (exosome) proteins, phosphoproteins and other

cancer-signaling molecules.

This technology, based on non-antibody affinity beads, is EVtrap

(Extracellular Vesicles Total Recovery and Purification) to help 

others learn more about cancer and other diseases.

Tymora Analytical routinely identifies over 1,000 unique proteins 

from EVs from only 0.01 mL of plasma or 0.2 mL of urine, a 

significant improvement over any prior data.

“A Non-Invasive, Low-Cost

Procedure to Detect

Cancer Biomarkers from Biological Fluids”

Take a look at out our outreach article published in Scientia, the leading science communication publication. In the article, we discuss our non-invasive approach of isolating EVs from biofluids to discover more protein biomarkers than in previous methods. We also explain how we’re growing our network of collaborators by offering our EV proteome analysis services to researchers like you.

Who should partner with Tymora?

Contract Research Organizations


If you conduct research for pharmaceutical, biotechnology, or medical device companies—with us, you can deliver innovative research and help them save costs on biomarker discovery and drug development.

Pharmaceutical and

Biotechnology Companies

If you work in pharmaceuticals or biotechnology, you can study biofluid samples with our non-invasive biomarker discovery to develop a companion diagnostic for your therapy.

Research Scientists and Clinical

Program Directors

If your career involves researching for cures or overseeing a research team, you can partner with Tymora Analytical to gain access to more effective, state-of-the-art technologies.

Why partner with Tymora Analytical?

Whether you’re researching biomarkers or developing a new drug, we understand how important your work is. That’s why we’ve developed a more effective way for you to analyze and develop new disease markers.

Currently, genetic screens dominate the market. However, genes just show one’s predisposition to developing a disease— for example, a 40% chance of getting breast cancer. In addition, CTCs and cfDNA are present at very low levels and are extremely difficult to detect at early stages.

Non-invasive protein analysis, on the other hand, provides real-time information about one’s disease progression. Tymora Analytical conducts this biopsy-free test using exosomes and other EVs so we can analyze what’s actually going on.

We’ve developed a new technology—EVtrap—to help other researchers detect thousands of active disease proteins and phosphoproteins from biofluids like blood, urine, and saliva. And, we would love to collaborate with you for more biomarker discoveries.

When you work with us, you're getting:

Innovative R&D products and services 

Unprecedented technology like EVtrap 


Accurate information about a disease’s 


Grant assistance for funding your research 


Helpful resources for ongoing education

PolyMAC-Ti Agarose Phosphopeptide Enrichment (complete kit) - 50 enrichments

조회수 26



PolyMAC-Ti Agarose Phosphopeptide Enrichment Kit

The Agarose PolyMAC-Ti Phosphopeptide Enrichment Kit is an alternative enrichment kit not requiring a magnetic separator rack. While generally considered less efficient and easy-to-use than the magnetic beads, this agarose gel-based kit still offers an outstanding solution for all enrichment needs. The kit contains: PolyMAC-Ti reagent, agarose capture gel, re-usable spin columns specially optimized for PolyMAC, loading buffer, capture buffer, washing buffer and elution buffer.   Protocol   Technical Document   Watch Video Protocol

SKU: 701. Categories: .

Product Description

PolyMAC for Phosphopeptide Enrichment - see data

  • Due to low stoichiometry of phosphorylation, phosphopeptide enrichment is a critical step for successful phosphoproteomics experiments.
  • Available here is a novel chemical strategy termed Polymer-based Metal-ion Affinity Capture (PolyMAC) for the isolation of phosphopeptides with exceptionally high reproducibility, selectivity and sensitivity.
  • PolyMAC is based on a metal-ion functionalized soluble nanopolymer to chelate phosphopeptides in a homogeneous aqueous environment.
  • Compared to current strategies based on solid phase micro- and nano-particles, PolyMAC demonstrates outstanding reproducibility, exceptional selectivity, fast chelation times, and high phosphopeptide recovery from complex mixtures.


After in-solution binding of phosphopeptides, PolyMAC needs to be captured covalently onto solid-phase beads to complete washing and elution steps. We offer capture based on magnetic beads (Recommended) or agarose beads and spin columns.